Treatment of Brucellosis Without Rifampicin
When rifampicin cannot be used, doxycycline 100 mg twice daily for 6 weeks combined with streptomycin 15 mg/kg daily IM for 2-3 weeks is the preferred first-line alternative, with doxycycline plus gentamicin 5 mg/kg daily IV/IM for 7 days as an acceptable substitute when streptomycin is unavailable.
Primary Alternative Regimens (Without Rifampicin)
The Ioannina Recommendations provide clear guidance on rifampicin-free options 1:
First-Line Alternative: Doxycycline-Streptomycin (DOX-STR)
- Dosing: Doxycycline 100 mg PO twice daily for 6 weeks + Streptomycin 15 mg/kg IM daily for 2-3 weeks
- Evidence grade: AI (highest recommendation level)
- Efficacy: This regimen is considered the "gold standard" alongside doxycycline-rifampicin 1
- Clinical data: Achieves 95.4% clinical response with only 4.6% relapse rate 2
- Meta-analysis support: Superior to doxycycline-rifampicin (OR = 3.17; 95% CI 2.05-4.91) 3
Preferred Practical Alternative: Doxycycline-Gentamicin (DOX-GENT)
- Dosing: Doxycycline 100 mg PO twice daily for 6 weeks + Gentamicin 5 mg/kg IV/IM daily for 7 days
- Evidence grade: BI
- Advantages: Wider availability than streptomycin; spares streptomycin for tuberculosis treatment 1
- Efficacy: Relapse rates comparable to WHO-recommended regimens (10-20% failure/relapse) 1
- Recent ranking: Ranked best in efficacy (SUCRA 0.94) in 2024 network meta-analysis 4
Second-Line Alternatives
Doxycycline-Cotrimoxazole (DCTM)
- Dosing: Doxycycline 100 mg PO twice daily + TMP-SMX 800/160 mg PO twice daily for 6 weeks
- Evidence grade: CII 1
- Efficacy: Similar to doxycycline-rifampicin 5, 3
- Special consideration: Preferred in tuberculosis-endemic regions to avoid rifampicin resistance 6
- Saudi Arabian experience: 96% cure rate with good serological response 6
Quinolone-Containing Regimens
- Dosing: Doxycycline 100 mg PO twice daily + Ofloxacin 400 mg PO twice daily OR Ciprofloxacin 500 mg PO twice daily for 6 weeks
- Evidence grade: CII 1
- Efficacy: Similar to doxycycline-rifampicin but with higher relapse rates 5, 2
- Limitations: Higher cost; risk of fluoroquinolone resistance development 1
- Recommendation: Reserve as alternative when other options unavailable 1
Important Clinical Considerations
Avoid Monotherapy
- Monotherapy has unacceptably high relapse rates (13% vs. 4.8% for combination therapy) 5
- TMP-SMX monotherapy showed 46% relapse rate 1
- Even doxycycline monotherapy, despite one favorable trial, is not recommended for routine use 1
Treatment Duration Matters
- Short-term treatment (<4 weeks) associated with 22% relapse rate vs. 4.8% for standard duration 5
- Six-week regimens are standard for uncomplicated brucellosis 1
Special Populations
Pediatric patients (<8 years): Cotrimoxazole plus rifampicin for 6 weeks is preferred 5. When rifampicin is contraindicated, gentamicin 5 days plus cotrimoxazole 6 weeks is suitable 5.
Common Pitfalls to Avoid
- Do not use rifampicin in tuberculosis-endemic areas where preserving rifampicin for TB treatment is critical 1, 6
- Monitor for relapse: Follow patients for 6 months with serial serology (SAT titers should decrease progressively) 6
- Ensure adherence: Non-adherence is the primary cause of relapse (4% in one series) 6
- Avoid newer fluoroquinolones (e.g., respiratory quinolones) for brucellosis to preserve them for other indications 1
Emerging Resistance Concerns
Recent data shows increasing resistance to both cotrimoxazole (3.4% prevalence) and rifampicin (4.6% prevalence), with temporal increases particularly in B. melitensis 7. This underscores the importance of combination therapy and appropriate antibiotic stewardship.
Monitoring Requirements
- Baseline hepatic enzymes, bilirubin, creatinine, CBC, and platelet count
- Monthly clinical assessment during therapy
- Serological follow-up at 6 and 12 months (expect progressive SAT titer decline: 1:1280→1:640→1:320) 6